Condition
Long Term Follow-Up
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Recruiting3
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06882317Enrolling By InvitationPrimary
Long Term Follow-up Study for Subjects Administered CLBR001
NCT07313878Not ApplicableRecruiting
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy
NCT04639778Not ApplicableRecruiting
Monitoring the Weight Evolution Using a Connected Scale
NCT06277037RecruitingPrimary
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
Showing all 4 trials